Efficacy of donor's purified CD34(+) cells for treatment of poor graft function following allogeneic hematopoietic stem cell transplantation.
10.7534/j.issn.1009-2137.2013.05.029
- Author:
Zhi-Hui LI
1
;
Xiao-Xiong WU
;
Yong-Bin CAO
;
Xiao-Hong LI
;
Ya-Mei WU
;
Pei LIU
;
Li-Xin XU
;
Pei YAN
;
Zhou-Yang LIU
;
Song-Wei LI
;
Xue-Liang YANG
Author Information
1. Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antigens, CD34;
Female;
Graft Survival;
Hematopoietic Stem Cell Transplantation;
Humans;
Male;
Middle Aged;
Tissue Donors;
Transplantation, Homologous;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(5):1228-1231
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to evaluate the efficacy and safety of donor's purified CD34(+) cells for treatment of secondary poor graft function (PGF) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Ten patients suffering from secondary PGF after allo-HSCT in our hospital from January 2009 to December 2011 were treated with the donor's purified and G-CSF mobilized CD34(+) cells. All the patients were observed for infusion-related complication and survival status. CliniMACS system was used to separate cells, the results of sorting purified and recovery rate were calculated and statistically analysed. The results showed that the purified of CD34(+) cells reached to (89.31 ± 1.73)%, and the recovery rate reached to (93.27 ± 8.14)%; 10 patients in the process of infusion did not suffer from seriously adverse complications, all of them obtained hematopoietic recovery, neither GVHD nor infection occurred after infusion of donor's purified CD34(+) cells. It is concluded that using CliniMACS system for donor's peripheral CD34(+) separation, both the purified and recovery of CD34(+) cells are satisfied, and the infusion of donor's purified CD34(+) cell is a safe and effective method to treat secondary PGF after allo-HSCT.
